Oral fluconazole for empiric treatment of prolonged fever in neutropenic patients: Prospective study in 250 consecutive patients after stem cell transplantation

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 4, 2004, Pages 328-332

  Stemmer, Salomon M ^a,b   Maor, Yasmin ^a   Hardan, Izhar ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Breast; Fluconazole; Neutropenic fever; Transplant

Indexed keywords

AMPHOTERICIN B; CARBOPLATIN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; THIOTEPA; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CELL COUNT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARBOPLATIN; CYCLOPHOSPHAMIDE; FEMALE; FEVER; FLUCONAZOLE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 3843146531     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000071943.54812.D4     Document Type: Article

References (24)

1. Armstrong D, Young LS, Meyer RD, et al. Infectious complications of neoplastic disease. Med Clin North Am 1971;55:729-45.
2. Hughes W, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
3. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
4. Walsh TJ, Eiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996;10:365-400.
5. Kibbler CC. Neutropenic infections: strategies for empirical therapy. J Antimicrob Chemother 1995;36(suppl 1B):107-17.
6. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(suppl 1):S161-9.
7. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
8. Kujathy P, Lerch K, Kochendorfer P, et al. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993;21:376-82.
9. Kauffman CA, Bradley SF, Ross SC, et al. Hepatosplenic candidiasis successful treatment with fluconazole. Am J Med 1991;91:137-41.
10. Goodman JL, Wintson DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
11. Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1994;13:3-11.
12. Wintson DJ, Chandrasekar P, Lazarus H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
13. Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission induction therapy for acute leukemia. Fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099-106.
14. Meunier F, Aoun M, Janssens M, et al. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole versus oral amphotericin B. Drug Invest 1991;3:258-65.
15. Viscoli C, Castagnola MT, Van-Lint V, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicenter, prospective and randomized clinical trial. Eur J Cancer 1996;32A:814-20.
16. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1996;10:102-10.
17. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:S668-72.
18. Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991;13:496-503.
19. Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998;105: 478-83.
20. Ellis ME, Halim MA, Spence D, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever - preliminary observations from a pilot, exploratory study. J Infect 1995;30:141-6.
21. Rotsrien C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999;28:331-40.
22. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double blind, multicenter trial. Clin Infect Dis 1999;28:250-5.
23. Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998;36(suppl 1):119-28.
24. Young GAR, Bosly A, Gibbs DL, et al.., and the Antifungal Prophylaxis Study Group. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukemia. Eur J Cancer 1999;35:1208-13.